skip to content
Detailed Quote
5i Report
Rating
B+

Review of Savaria

OCT 21, 2021 - Savaria is a small player in the accessibility solutions segment, which is why it focuses on acquisitions for growth. Management has focused on expanding the product line and diversifying revenue streams and has positioned SIS towards becoming a one-stop shop. We maintain the rating at ‘B+’.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions

Q: Can you supply a few suggestions of dividend stocks that may be good to purchase during tax loss selling? Canadian and US if possible.
A few growth stocks would be a good balance to this question as well! Thanks, James

Read Answer Asked by JAMES on November 28, 2022

Q: I just sold off my Biogen holding and am looking for a replacement within the healthcare sector. I held Biogen for over 3 years and exited with a nice return, but I have to say that I did not enjoy the wild ride and price swings as it seemed to trade solely on its new Alzheimer’s drug advancements and setbacks. So now I am looking to replace it with something a little more stable but still with the expectation of slow and steady growth. What would be your top 1 or 2 picks be today for both the US and Canada that might fit. I already own Savaria and XLV so something besides these.

Read Answer Asked by Steven on November 18, 2022
Insiders
Share Information
News and Media
Looking for more? Sign up for a FREE 14 day trial !

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!